Bayer HealthCare on Tuesday announced that the Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for Bayer's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis.
Cefaly Technology announced Wednesday that the Cefaly medical device for the preventive treatment of migraine headaches is available for purchase and delivery in the United States for patients with a medical prescription at Cefaly.us.
Allergan on Tuesday confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals to acquire all of the outstanding shares of the company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of Allergan.
Eli Lilly on Monday announced that the Food and Drug Administration has approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
In what appears to be a marketing first, natural personal care brand Burt’s Bees is reportedly introducing promotional messages that appear as appointments in electronic calendars on computers, smartphones and tablets, according to a New York Times article.
Maybelline New York has named Yadim Carranza as the brand's global makeup artist, providing artistic vision for Maybelline New York makeup and becoming the voice of the brand to consumers, press and industry influencers.
A new health economic study shows potential healthcare savings of $12.7 billion per year if U.S. adults would increase their dietary fiber to about 25 grams, the minimum level recommended by health experts for adults.
This year is bound to be interesting for beauty as the industry is likely to see an increased focus on innovation, blurring of the lines and multi-functionality — a 2014 trend research firm Mintel has coined as “mixologiste.”
GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia for whom fludarabine-based therapy is considered inappropriate.